Agomelatine in the treatment of major depressive disorder

@article{Kennedy2010AgomelatineIT,
  title={Agomelatine in the treatment of major depressive disorder},
  author={Sidney H. Kennedy and Sakina J. Rizvi},
  journal={CNS Drugs},
  year={2010},
  volume={24},
  pages={479-499}
}
To demonstrate the clinical effectiveness of an antidepressant drug requires evidence beyond short- and long-term efficacy, including a favourable adverse-effect profile and sustained treatment adherence. Under these conditions, patients should experience enhanced social and functional outcomes. The novel antidepressant agomelatine, a melatonergic MT1/MT2 receptor agonist with serotonin 5-HT2C receptor antagonist activity, displays antidepressant efficacy with a favourable adverse-effect… Expand
Agomelatine: A narrative review
TLDR
Results from clinical trials with agomelatine have shown that it is efficacious in both the acute phase and the continuation phase of treatment of depression, and efficacy has also been demonstrated in severe depression and in treating anxiety symptoms associated with major depression. Expand
Review: The antidepressant agomelatine improves the quality of life of depressed patients: implications for remission
  • P. Llorca
  • Psychology, Medicine
  • Journal of psychopharmacology
  • 2010
TLDR
Treatment with agomelatine is suggested to provide more sustained, longer-term remission because antidepressant efficacy is combined with fewer residual symptoms and better tolerability and adherence. Expand
Efficacy and tolerability of agomelatine in the treatment of depression
TLDR
The new antidepressant agomelatine, a melatonergic MT1/MT2 agonist and 5-HT2C receptor antagonist, has exhibited good antidepressant efficacy in acute, short-term, and long-term treatment. Expand
Agomelatine as monotherapy for major depression: an outpatient, open-label study
TLDR
This study showed good short-term efficacy for agomelatine in outpatients with major depressive episodes, and achieved significant improvements in daily functioning of patients, and had good tolerability. Expand
Review: The importance of early symptom relief in antidepressant treatment: focus on agomelatine
  • R. Lam
  • Psychology, Medicine
  • Journal of psychopharmacology
  • 2010
TLDR
The new antidepressant agomelatine, with its novel pharmacological profile as an agonist at melatonergic (MT1 and MT2) receptors and antagonist at 5-HT2C receptors, has in several studies produced earlier symptom improvement than comparator selective serotonin reuptake inhibitors and serotonin—noradrenaline reuptakes inhibitors, suggesting that it can be considered a first-line treatment for patients with major depression. Expand
Agomelatine in the Treatment of Major Depressive Disorder: An Assessment of Benefits and Risks
  • M. Gahr
  • Medicine
  • Current neuropharmacology
  • 2014
TLDR
Its unique mechanism of action with particular sleep modulating effects may represent a specific treatment strategy for patients with particular characteristics; further studies with thorough characterization of patients are needed to test this hypothesis. Expand
[Agomelatine in the treatment of major depressive disorder: assessment of the efficacy and tolerability].
TLDR
The heterogeneous clinical manifestations of MDD and the unique mechanism of action of agomelatine with the ability of the drug to have a modulating effect on sleep, make it possible to effective use it for treating such disorders. Expand
Melatonergic Antidepressant Agomelatine and Its Efficacy in Depressive Disorders
TLDR
Clinical studies undertaken on patients with major depressive disorders, bipolar depression, and seasonal affective disorder have shown that agomelatine is clinically very effective in reducing depressive symptoms and improved sleep efficiency and resynchronized the disrupted circadian rhythms in some studies. Expand
Agomelatine for Depression in Schizophrenia: A Case-Series.
TLDR
Initial evidence is provided that agomelatine is safe and efficacious in treating depressive symptoms in patients with schizophrenia and seems to be effective for the treatment of negative symptoms. Expand
Superior antidepressant efficacy results of agomelatine versus fluoxetine in severe MDD patients: a randomized, double-blind study
TLDR
In this study, agomelatine showed superior antidepressant efficacy over fluoxetine in treating patients with a severe episode of major depressive disorder after 8 weeks of treatment with a good tolerability profile. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 87 REFERENCES
Efficacy of agomelatine, a MT1/MT2 receptor agonist with 5-HT2C antagonistic properties, in major depressive disorder.
  • J. Olié, S. Kasper
  • Psychology, Medicine
  • The international journal of neuropsychopharmacology
  • 2007
TLDR
It is confirmed that agomelatine is effective in treating major depression, including the most severely depressed patients, with a good safety and tolerability profile, therefore providing physicians with an effective pharmacological approach to antidepressant therapy. Expand
Agomelatine prevents relapse in patients with major depressive disorder without evidence of a discontinuation syndrome: a 24-week randomized, double-blind, placebo-controlled trial.
TLDR
Agomelatine is an effective and safe antidepressant continuation therapy, which confirms efficacy seen in short-term studies, and underlines the novel clinical profile of agomel atine, which quite likely reflects its innovative pharmacology. Expand
Placebo-controlled trial of agomelatine in the treatment of major depressive disorder
TLDR
The results support the prescription of agomelatine 25 mg as the usual therapeutic dose, and suggest that increasing the dose to 50 mg may be beneficial for some patients without reducing tolerability. Expand
Escitalopram maintenance treatment for prevention of recurrent depression: a randomized, placebo-controlled trial.
TLDR
Maintenance treatment with escitalopram was well tolerated and significantly reduced the risk for recurrence of depression, demonstrating the need for maintenance therapy of recurrent major depressive disorder beyond 4 to 6 months of initial symptom resolution even if few residual symptoms are present. Expand
Efficacy of the novel antidepressant agomelatine on the circadian rest-activity cycle and depressive and anxiety symptoms in patients with major depressive disorder: a randomized, double-blind comparison with sertraline.
TLDR
Higher efficacy results were observed with agomelatine as compared to sertraline on both depressive and anxiety symptoms over the 6-week treatment period, together with a good tolerability profile. Expand
Improvement in subjective sleep in major depressive disorder with a novel antidepressant, agomelatine: randomized, double-blind comparison with venlafaxine.
TLDR
Agomelatine showed similar antidepressant efficacy with earlier and greater efficacy in improving subjective sleep than venlafaxine in MDD patients. Expand
Efficacy of Agomelatine in Generalized Anxiety Disorder: A Randomized, Double-Blind, Placebo-Controlled Study
TLDR
This study suggests that agomelatine is effective in the treatment of GAD and is well tolerated, and additional trials, using an active comparator and extending over a longer period, are needed to delineate the place of agomalatine in the contemporary pharmacotherapy for anxiety disorders. Expand
Escitalopram in the treatment of major depressive disorder: A meta-analysis
TLDR
In this meta-analysis, superior efficacy of escitalopram compared to SSRIs and SNRIs was confirmed, although the superiority over SSR Is was largely explained by differences between escitalobram and citaloprams. Expand
A Double-Blind Comparison of Sexual Functioning, Antidepressant Efficacy, and Tolerability Between Agomelatine and Venlafaxine XR
TLDR
Agomelatine seems to be an efficacious antidepressant with a superior sexual side effect profile compared with venlafaxine XR, although superiority to placebo was not evaluated in this trial. Expand
Determination of the dose of agomelatine, a melatoninergic agonist and selective 5-HT2C antagonist, in the treatment of major depressive disorder: a placebo-controlled dose range study
TLDR
It is demonstrated that agomelatine is efficient in the treatment of major depressive disorder and that 25 mg is the target dose. Expand
...
1
2
3
4
5
...